Announcements Items
July 2, 2012

Tegal acquisition of CollabRx will bring interpretive content and data analytics to genomics-based medicine

Announcements, In the News By: ams

Petaluma, Calif., July 2, 2012 — Tegal Corporation (NASDAQ: TGAL) today announced that it has signed a definitive agreement to acquire CollabRx, Inc., a privately held technology company in the rapidly growing market of interpretive content and data analytics for genomics-based medicine.

CollabRx offers cloud-based expert systems that provide clinically relevant interpretive knowledge to institutions, physicians, researchers and patients for genomics-based medicine in cancer and other diseases to inform health care decision making. With access to approximately 50 clinical and scientific advisors at leading academic institutions and a suite of tools and processes that combine artificial intelligence-based analytics with proprietary interpretive content, the company is well positioned to participate in the $300 billion value-added “big data” opportunity in the US health care market (as reported by McKinsey Global Institute), over half of which specifically targets areas in cancer and cancer genomics.1

The Chief Executive Officers of the two constituent companies, Thomas Mika of Tegal and James Karis of CollabRx, plan to serve as co-CEOs of the combined, publicly traded company, with headquarters in San Francisco, CA. Tegal entered into an employment agreement with Mr. Karis that will become effective at the closing, and Mr. Karis will also be appointed to Tegal’s Board of Directors. Tegal will continue to operate under its current name and ticker symbol for the time being, but plans to seek stockholder approval at its upcoming annual meeting in September 2012 for an amendment to its Certificate of Incorporation, changing its corporate name to CollabRx, Inc.

Originally founded in 2008 by Silicon Valley Internet pioneer Jay (Marty) Tenenbaum, CollabRx has developed clinical advisory networks, expert systems, proprietary tools and processes, and a pipeline of commercial data products and applications (“apps”) for cancer. CollabRx Therapy Finders™, its first commercial product, provides sophisticated, credible, personalized, and actionable information to physicians and patients for rapidly determining which medical tests, therapies, and clinical trials may be considered in cancer treatment planning with a specific emphasis on the tumor genetic profile.

CollabRx Therapy Finders™ are web-based apps that serve as one type of user interface to access proprietary CollabRx content. CollabRx content is dynamically updated and organized in a knowledgebase that includes information on molecular diagnostics, medical tests, clinical trials, drugs, biologics and other information relevant for cancer treatment planning. Capturing how highly respected practicing physicians use this information in the clinical setting further refines the knowledgebase.

Upon the acquisition’s closing, Tegal will issue an aggregate of 236,433 shares of common stock, representing 14% of Tegal’s total shares outstanding prior to the closing, to former CollabRx stockholders in exchange for 100% of the capital stock of CollabRx, Inc. Tegal and certain former CollabRx stockholders will enter into a Stockholders Agreement providing for, among other things, registration rights, transfer restrictions and voting and standstill agreements. Tegal also will assume $500,000 of existing CollabRx indebtedness through the issuance of 5-year promissory notes in substitution for outstanding notes previously issued by CollabRx. In addition, Tegal will grant a total of 368,417 RSUs and options as “inducement grants” to newly hired management and employees, all subject to four-year vesting and other restrictions.

“Medicine is entering a new era of low cost genome sequencing and the proliferation of personalized treatments based on specific genetic mutations,” said James Karis, CEO of CollabRx. “With the technology platform and expert system leadership position that CollabRx has developed over the past few years, we believe that the new company is in a position to lead the market for accurate, credible and current genomic information in the cancer space. We are excited to be joining the Tegal management team in a well-resourced, publicly-traded entity.”

“This acquisition marks both the successful conclusion of a transition process and the beginning of a new chapter for Tegal Corporation,” said Thomas Mika, Tegal’s Chairman, President and CEO. “We are excited to help drive the rapid growth of this market while we meet a critical and consequential human need. This is a mission Tegal’s board has embraced wholeheartedly. I am very pleased to be working with James Karis as Co-CEO and fellow director, and look forward, along with the entire team at CollabRx and Tegal, to building a dynamic company in a new era of genomic medicine.”

1 ”Big data: The next frontier for innovation, competition and productivity”, McKinsey Global Institute, May 2011

About Tegal

Since its founding in 1972, Tegal Corporation has been dedicated to the development and application of emerging technologies. For 40 years, Tegal’s process and equipment know-how has been incorporated in devices fabricated by some of the world’s leading semiconductor and MEMS companies, including Tegal’s one-time parent, Motorola. Now entering its fifth decade, Tegal has committed its future to emerging technologies in medical devices and health care. Please visit us on the web at www.tegal.com.

About CollabRx

CollabRx is a recognized leader in “cloud-based” expert systems to inform health care decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care.

Safe Harbor Statement

This press release contains forward-looking statements that may include statements regarding the intent, belief or current expectations of Tegal, CollabRx and their respective management. Forward looking statements include statements about the benefits and advantages of the acquisition for Tegal and CollabRx. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including but not limited to the risk that the acquisition will not close as the transaction is subject to certain closing conditions. In addition, if and when the transaction is closed, there will be risks and uncertainties related to Tegal’s ability to integrate CollabRx successfully, the risk that the anticipated benefits from the acquisition may not be fully realized or may take longer to realize than expected; and competition and its effect on the combined company’s performance. Additional factors that may affect future results are contained in the SEC filings for Tegal, including but not limited to Tegal’s Annual Report on Form 10-K for the year ended March 31, 2012. Tegal and CollabRx each disclaim any obligation to update and revise statements contained in this release based on new information or otherwise.

Contact:

Tegal Corporation
Thomas Mika, President & CEO
(707) 763-5600 x5630
tmika@tegal.com

 

November 3, 2008

PatientsLikeMe Report Indicates MS Patients Still Positive for Tysabri Following July Announcement of PML Cases

Announcements By: ams

CAMBRIDGE, MA., November 3, 20089

PatientsLikeMe, the leading online community for patients with life-changing conditions, announces the release of its newest PatientsLikeMeListen(TM) report: “Did the July 2008 PML announcement affect the Tysabri brand?” Among its findings, the report reveals that patients retained an overall positive perception of the Tysabri brand despite the July 2008 announcement of two additional PML cases.

PatientsLikeMe is a CommerceNet portfolio company.

Read full press release

October 29, 2008

Vivaty Everywhere: Embeddable Scenes Now Make It Possible to Cut and Paste Web-Based Virtual Scenes into Any Blog, Site Brand, or Online Destination

Announcements By: ams

Leading Entertainment and Political Brands Launch Customized Vivaty-Embedded Scenes

MENLO PARK, CALIF., October 29, 2008–Vivaty Inc. today launched Vivaty Everywhere, the company’s new addition to its Web-based virtual world platform.

Vivaty is a CommerceNet portfolio company.

Read full press release

September 30, 2008

OpenFindings.org Launches Collaborative Site, Creating New Ways to Gather and Visualize Health Data

Announcements By: ams

OpenFindings, a new CommerceNet initiative, has launched a collaborative site (beta) that supports research and patient communities, making healthcare information more readily available to everyone.

Community Site Offers Sharing and Visualization
OpenFindings collects health data from widespread public sources and makes it accessible with easy-to-understand graphs and charts. Thumbnail images enable users to compare and contrast groups of data in a single place, without having to construct queries or build custom programs.

OpenFindings transforms complex tabular data into dynamic graphs that enable visualization of demographic distributions and time and geographic trends. One-click navigation makes it easy for community members to discover, browse, and build new graphs.

A Call for Volunteers
OpenFindings’ mission is to catalyze the science and public health communities to share data and further scientific discourse and discovery. Join us!

OpenFindings seeks web designers, web developers, database programmers, and other volunteers to help build out the beta community site. OpenFindings may also need individuals familiar with nonprofit administration and grant writing.

Contact Lisa Dusseault at OpenFindings to learn more.

September 9, 2008

PatientsLikeMe Receives Prix Ars Electronica Honors

Announcements By: ams

CAMBRIDGE, MA., September 9, 2008

PatientsLikeMe, the leading online community for patients with life-changing conditions, receives high honors from Ars Electronica, the premier center for art and technology, this month. The Prix Ars Electronica is a highly regarded international award for “creativity and pioneering spirit in the field of digital media.” PatientsLikeMe is one of two companies to receive an “Award of Distinction” in the Digital Communities category.

PatientsLikeMe is a CommerceNet portfolio company.

Read full press release

August 12, 2008

Spout Launches New FanKits Service, a Powerful Social Media Marketing Tool

Announcements By: ams

Sony Pictures Entertainment Partners with Sprout to Harness the Power of Their FanKits Service to Connect Its Brand with Fans

San Francisco, CA–August 12, 2008, Sprout, the premier platform for easily creating, publishing, and managing rich media Web content, today announced the launch of its FanKits service. FanKits enable entertainment and media companies to connect and promote their branded content to consumers by allowing fans to create and share widgets within social media sites.

Sprout Builder, a Web-based authoring environment for creating sophisticated Flash content, is a product of ChipIn, a CommerceNet portfolio company.

Read full press release

July 11, 2008

Robert Rodin to Serve on Prestigious Panel of Judges for Live Edge 2008

Announcements By: ams

Premier Farnell plc, a leading multichannel, high-service distributor supporting millions of engineers and purchasing professionals, named CommerceNet board and executive committee member Robert Rodin to its panel of judges for Live Edge 2008. This will be Mr. Rodin’s second year judging the competition.

Live Edge 2008 is a competition focused on electronic design for the global environment. Last year’s inaugural event was a huge success, with thousands of electronic design engineers and students from over 102 countries worldwide sharing their innovative designs for products aimed at reducing humankind’s environmental impact on the planet.

July 8, 2008

PatientsLikeMe Geneticist, Catherine Brownstein, Ph.D. Wins Prestigious Research Award

Announcements By: ams

CAMBRIDGE, MA., July 08, 2008

PatientsLikeMe is proud to announce that team geneticist Catherine Brownstein, Ph.D. will receive the 2008 Young Investigator Award from the American Society for Bone and Mineral Research (ASBMR). The award, given for Dr. Brownstein’s post-graduate creation and study of the Klotho/HYP double knockout mouse, which further elucidates the genes responsible for bone density and phosphate metabolism, will be conferred this September at the ASBMR annual meeting in Montreal, Canada.

PatientsLikeMe is a CommerceNet portfolio company.

Read full press release

May 6, 2008

PatientsLikeMe Featured in the New York Times Magazine

Announcements, Uncategorized By: ams

CommerceNet portfolio company, PatientsLikeMe, is featured in a New York Times Magazine article, “Practicing Patients,” by Thomas Goetz.

“At first glance, [PatientsLikeMe] looks like just any other online community, a kind of MySpace for the afflicted. Members have user names, post pictures of themselves and post updates and encouragements. As such, it’s related to the chat rooms and online communities that have inhabited the Internet for more than a decade.

But PatientsLikeMe seeks to go a mile deeper than health-information sites like WebMD or online support groups like Daily Strength. The members of PatientsLikeMe don’t just share their experiences anecdotally; they quantify them, breaking down their symptoms and treatments into hard data. They note what hurts, where and for how long. They list their drugs and dosages and score how well they alleviate their symptoms. All this gets compiled over time, aggregated and crunched into tidy bar graphs and progress curves by the software behind the site. And it’s all open for comparison and analysis. By telling so much, the members of PatientsLikeMe are creating a rich database of disease treatment and patient experience.”

>Read the full article

May 6, 2008

CommerceNet Portfolio Company—CollabRx—Accelerates the Discovery of Effective Treatments and Permanent Cures

Announcements, Uncategorized By: ams

CollabRx, one of CommerceNet’s latest portfolio companies, applies collaborative science to slash the time, cost, and risk of therapy development for neglected diseases.

CollabRx builds and operates virtual biotechs for foundations and patients who urgently seek cures for their diseases. The CollabRx research platform connects researches to one another and to a network of scientific services, providing unprecedented opportunities for knowledge sharing and economies of scale.

Learn more